Technology
Health
Medical

AtriCure

$29.51
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.20 (0.68%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell AtriCure and other stocks, options, ETFs, and crypto commission-free!

About

AtriCure, Inc. engages development, manufacture and sale of devices designed primarily for the surgical ablation of cardiac tissue, and systems for the exclusion of the left atrial appendage. Its products include radio Frequency (RF) ablation pacing and sensing, cryo, left atrial appendage management, soft tissue dissection, estech surgical instrumentation, and cart configuration. Read More It operates through the following geographical segments: United States, Europe, Asia, Other International, and Total International. The company was founded by Michael D. Hooven on October 31, 2000 and is headquartered in West Chester, OH.

Employees
620
Headquarters
Mason, Ohio
Founded
2000
Market Cap
1.13B
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
224.76K
High Today
$29.62
Low Today
$29.28
Open Price
$29.37
Volume
12.80K
52 Week High
$36.49
52 Week Low
$23.61

Collections

Technology
Health
Medical
Radio
Broadcasting
Media
US
North America

News

Yahoo FinanceMay 2

Hedge Funds Have Never Been More Bullish On AtriCure Inc. (ATRC)

The government requires hedge funds and wealthy investors that crossed the $100 million equity holdings threshold are required to file a report that shows their positions at the end of every quarter.

33
NasdaqApr 26

AtriCure Inc (ATRC) Q1 2019 Earnings Call Transcript

Image source: The Motley Fool. AtriCure Inc (NASDAQ: ATRC) Q1 2019 Earnings Call April 25, 2019 , 4:30 p.m. ET Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Operator Good afternoon, and welcome to AtriCure's First Quarter 2019 Earnings Conference Call. (Operator Instructions) As a reminder, this call is being recorded for replay purposes. I would now like to turn the call over to Lynn Lewis from the Gilmartin Group for a few introductory comments. Lynn Piep...

16
BusinessWireApr 23

AtriCure Announces First Patient Enrollment in the DEEP IDE Trial Restart

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatment for atrial fibrillation (Afib) and left atrial appendage management, today announced the restart of the Dual Epicardial and Endocardial Procedure (DEEP) clinical trial (NCT02393885). Following approval by the FDA to restart the trial and enroll an additional 40 subjects, which was granted in December 2018, the first patient was treated by a team led by Professor Mark La Meir and Professor Carlo de Asmundis...

5

Earnings

-$0.31
-$0.23
-$0.16
-$0.08
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Jul 31, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.